Research Article
High Intestinal and Systemic Levels of Interleukin-23/T-Helper 17 Pathway in Chinese Patients with Inflammatory Bowel Disease
Table 1
Demographic characteristics and clinical features of the patients with UC, CD, and healthy controls.
| | Characteristics | UC
( (%)) | CD
( (%)) | Healthy controls
( (%)) |
| | Male | | 54 (45.76) | 19 (63.33) | 65 (69.89) | | Age (years) mean ± SD (range) | | (10–67) | (17–61) | (21–88) | Course of disease (years)
Mean ± SD (range) | | (1.25, 0.003–23) | (1.29, 0.08–16) | — | | Smoke habit | | 24 (20.34) | 7 (23.33) | — | | Family history | | 13 (11.02) | 0 | — | | Extraintestinal manifestations | | 33 (27.97) | 16 (53.33) | — |
| | Disease location | | | | | UC | CD | | | | | Left sided colitis | Colon | 35 (29.66) | 7 (23.33) | — | | Extensive colitis | Ileocolon | 36 (30.51) | 9 (30.00) | — | | Proctitis | Ileum | 47 (39.83) | 14 (46.66) | — |
| | Disease behavior | | | | | UC | CD | | | | | Initial onset | Stricturing | 54 (45.76) | 4 (13.33) | — | | Chronic relapse | Nonstricturing, Nonpenetrating | 57 (48.31) | 19 (63.33) | — | | Chronic continuous | Penetrating | 7 (5.93) | 7 (23.33) | — | | Active disease | | 90 (76.27) | 20 (66.67) | — | | Inactive disease | | 28 (23.73) | 10 (33.33) | — |
| | Treatment | | | | | 5-ASA/SASP | | 103 (87.29) | 23 (76.67) | — | | Steroid | | 52 (44.07) | 9 (30.00) | — | | Antibiotics | | 28 (23.73) | 2 (6.67) | — | | Immunosuppressive | | 9 (7.63) | 5 (16.67) | — | | Infliximab | | 1 (0.85) | 4 (13.33) | — | | Operation | | 0 | 5 (16.67) | — |
|
|
SD: standard deviation; 5-ASA: 5-aminosalicylate; SASP: sulfasalazine.
|
